[print
friendly page]
Meprobamate
Meprobamate was introduced
as an anti-anxiety agent in 1955 and is prescribed primarily to treat
anxiety, tension, and associated muscle spasms. More than 50 tons are
distributed annually in the United States under its generic name and brand
names such as Miltown® and Equanil®. Its onset and duration
of action are similar to the intermediate-acting barbiturates; however,
therapeutic doses of meprobamate produce less sedation and toxicity than
barbiturates. Excessive use can result in psychological and physical dependence.
Carisoprodol (Soma®), a skeletal muscle relaxant, is metabolized
to meprobamate. This conversion may account for some of the properties
associated with carisoprodol and likely contributes to its abuse.
|